ArticleCureus2026
Pediatric Primary Diffuse Leptomeningeal Melanomatosis: A Case Report and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary diffuse leptomeningeal melanomatosis (PDLM) is an exceptionally rare and aggressive pediatric central nervous system (CNS) malignancy that often presents with nonspecific symptoms, leading to delayed diagnosis. We report a seven-year-old boy who initially presented with recurrent focal neurologic episodes and headaches that were attributed to migraine before progressive visual changes and signs of elevated intracranial pressure (ICP) prompted further evaluation. Cerebrospinal fluid (CSF) cytology and meningeal biopsy confirmed PDLM with diffuse leptomeningeal involvement. Despite rapid neurologic decline after initiation of immunotherapy, urgent cranial and later spinal radiotherapy resulted in meaningful functional recovery, allowing temporary stabilization, return to school, and preservation of quality of life. Disease progression ultimately occurred, and he died 16 months after symptom onset. This case highlights the diagnostic challenges of PDLM and highlights the potential role of radiotherapy in providing neurologic improvement and symptomatic benefit, even in the setting of limited overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.